-
公开(公告)号：US09827207B2
公开(公告)日：2017-11-28
申请号：US14933598
申请日：2015-11-05
发明人： Richard D. Hamlin , Amit Jain , Jianye Wen
IPC分类号： A61K31/135 , A61K47/32 , A61K9/70
CPC分类号： A61K9/7061 , A61K9/7084 , A61K31/135
摘要： Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
-
公开(公告)号：US09763880B2
公开(公告)日：2017-09-19
申请号：US15066087
申请日：2016-03-10
发明人： Kiichiro Nabeta
IPC分类号： A61K31/335 , A61K9/10 , A61K31/337 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/44
摘要： Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
-
公开(公告)号：US09427435B2
公开(公告)日：2016-08-30
申请号：US14492509
申请日：2014-09-22
发明人： Kiichiro Nabeta , Toru Hibi
IPC分类号： A61K31/4468 , A61P29/00 , A61K9/00 , A61K9/107 , A61K47/10 , A61K47/24 , A61K47/12 , A61K47/44
CPC分类号： A61K31/4468 , A61K9/0019 , A61K9/107 , A61K47/10 , A61K47/12 , A61K47/24 , A61K47/44
摘要： Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.
摘要翻译： 提供了治疗受试者癌症疼痛的方法和组合物。 在本发明的方法中，通过向受试者施用有效量的麻醉乳剂，例如芬太尼乳液，制剂，治疗受试者的癌症疼痛。 在某些实施方案中，乳液制剂包括麻醉活性剂，油，水和表面活性剂。 还提供了制备主题乳液制剂的方法以及包括乳液制剂的试剂盒。
-
公开(公告)号：US09308195B2
公开(公告)日：2016-04-12
申请号：US14564384
申请日：2014-12-09
发明人： Kiichiro Nabeta
摘要： Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
摘要翻译： 提供非水，无乙醇的紫杉烷制剂。 本发明的实施方案的制剂包括紫杉烷，油，非离子表面活性剂，非水溶剂和有机酸组分，其中有机酸组分可溶于非水溶剂中， 非离子表面活性剂等于或大于非水溶剂的重量。 还提供了使用制剂的方法，以及包括制剂的试剂盒。 提供非水，无乙醇的多西紫杉醇制剂。 本发明实施方案的制剂包括多西他赛，油，非离子表面活性剂，非水溶剂和可溶于非水溶剂中并基本上不含任何共轭碱的有机酸。 还提供了使用制剂的方法，以及包括制剂的试剂盒。
-
公开(公告)号：US20150094361A1
公开(公告)日：2015-04-02
申请号：US14564384
申请日：2014-12-09
发明人： Kiichiro Nabeta
摘要： Non-aqueous, ethanol-free taxane formulations are provided. Formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the formulations, as well as kits that include the formulations. Non-aqueous, ethanol-free docetaxel formulations are provided. Formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the formulations, as well as kits that include the formulations.
摘要翻译： 提供非水，无乙醇的紫杉烷制剂。 本发明的实施方案的制剂包括紫杉烷，油，非离子表面活性剂，非水溶剂和有机酸组分，其中有机酸组分可溶于非水溶剂中， 非离子表面活性剂等于或大于非水溶剂的重量。 还提供了使用制剂的方法，以及包括制剂的试剂盒。 提供非水，无乙醇的多西紫杉醇制剂。 本发明实施方案的制剂包括多西他赛，油，非离子表面活性剂，非水溶剂和可溶于非水溶剂中并基本上不含任何共轭碱的有机酸。 还提供了使用制剂的方法，以及包括制剂的试剂盒。
-
公开(公告)号：US08871791B2
公开(公告)日：2014-10-28
申请号：US12685401
申请日：2010-01-11
申请人： Kiichiro Nabeta , Toru Hibi
发明人： Kiichiro Nabeta , Toru Hibi
CPC分类号： A61K31/4468 , A61K9/0019 , A61K9/107 , A61K47/10 , A61K47/12 , A61K47/24 , A61K47/44
摘要： Methods and compositions of treating a subject for cancer pain are provided. In the subject methods, a subject is treated for cancer pain by administering to the subject an effective amount of a narcotic emulsion, e.g., fentanyl elmulsion, formulation. In certain embodiments, the emulsion formulations include a narcotic active agent, oil, water and a surfactant. Also provided are methods of making the subject emulsion formulations as well as kits that include the emulsion formulations.
摘要翻译： 提供了治疗受试者癌症疼痛的方法和组合物。 在本发明的方法中，通过向受试者施用有效量的麻醉乳剂，例如芬太尼乳液，制剂，治疗受试者的癌症疼痛。 在某些实施方案中，乳液制剂包括麻醉活性剂，油，水和表面活性剂。 还提供了制备主题乳液制剂的方法以及包括乳液制剂的试剂盒。
-
7.发明申请公开(公告)号：US20140088181A1
公开(公告)日：2014-03-27
申请号：US14025695
申请日：2013-09-12
发明人： Kiichiro Nabeta
IPC分类号： A61K9/107 , A61K31/337
CPC分类号： A61K9/107 , A61K9/143 , A61K9/145 , A61K31/337
摘要： Taxane pro-emulsion formulations are provided. Pro-emulsion formulations are dried powders that include a taxane, oil, surfactant and sugar alcohol. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.
摘要翻译： 提供了紫杉烷乳液制剂。 预乳液制剂是包括紫杉烷，油，表面活性剂和糖醇的干燥粉末。 还提供了制备和使用前乳液制剂的方法，以及包括前乳液制剂的试剂盒。
-
公开(公告)号：US08475837B2
公开(公告)日：2013-07-02
申请号：US12952516
申请日：2010-11-23
IPC分类号： A61K9/70
CPC分类号： A62D3/33 , A61J1/00 , A61J1/14 , A61K9/7084 , A61K31/445 , A62D3/00 , A62D2101/26 , B09B3/0075 , B09B2220/14 , B65D25/14
摘要： The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.
-
公开(公告)号：US20130018298A1
公开(公告)日：2013-01-17
申请号：US13623718
申请日：2012-09-20
发明人： Todd A. Krinke
CPC分类号： A61N1/303 , A61N1/0428 , A61N1/044 , A61N1/0448 , A61N1/30 , A61N1/325
摘要： The present invention relates generally to iontophoretic drug delivery systems for transdermal delivery of therapeutic agents and, more particularly, to packaging such systems for long shelf life and easy assembly for use. The system package includes an iontophoretic skin worn patch component that accommodates a power source, electronics, electrodes and a drug pack component that carries a therapeutic agent which is contained as a separate sealed component. The packaged system further provides for ease of assembly at the time of use.
摘要翻译： 本发明一般涉及用于经皮递送治疗剂的离子电渗药物递送系统，更具体地涉及包装这种系统以保持长期的保质期和易于使用的组装。 系统包装包括离子电渗皮肤磨损的贴片组件，其容纳电源，电子器件，电极和携带治疗剂的药物组分，其作为单独的密封组分包含。 该包装系统进一步提供了在使用时易于组装。
-
公开(公告)号：US08239018B2
公开(公告)日：2012-08-07
申请号：US12868123
申请日：2010-08-25
IPC分类号： A61N1/30
CPC分类号： A61N1/0436 , A61N1/044
摘要： An electrode assembly for use in an iontophoresis device for the transcutaneous administration of an active therapeutic species has a base layer of including a linking conductive base material which is consumed (oxidizes or reduces) preferentially to water, a first upper layer of sacrificial material coated on a first portion of the base layer wherein the sacrificial material is consumed preferentially to the linking conductive base material of the base layer. A second upper layer of non-conducting material is coated on a second portion of the base layer, the second upper layer being spaced from the first upper layer, connected by a narrow exposed linking area of the base layer material remaining exposed therebetween. During operation of an associated iontophoresis device, the sacrificial material will be sequentially consumed; the first upper layer will be fully consumed followed by the linking conductive base material of the exposed linking area of the base layer which severs the base layer thereby breaking circuit continuity disabling activity in the device. A visual indicator may be provided allowing a wearer to monitor the state of reaction of the linking area.
摘要翻译： 用于经皮给药活性治疗物种的离子电渗疗法装置的电极组件具有包含优先吸收（氧化或还原）水的连接导电基材的基层，涂覆在第一上层的牺牲材料 基底层的第一部分，其中牺牲材料优先地消耗到基底层的连接导电基底材料。 第二上层非导电材料被涂覆在基层的第二部分上，第二上层与第一上层隔开，第二上层由保留在其间的基层材料的窄暴露的连接区连接。 在相关联的离子电渗装置的操作期间，牺牲材料将被顺序消耗; 第一上层将被完全消耗，之后是基底层的暴露的连接区域的连接导电基底材料，其切断基底层，从而破坏器件中的电路连续性失效活动。 可以提供视觉指示器，允许佩戴者监视连接区域的反应状态。
-
-
-
-
-
-
-
-
-
搜索结果
65 条记录 (耗时 0.037 秒)
